Monitoring Agency Report for the Quarter-III ended on December 31, 2025
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma has submitted the quarterly Monitoring Agency Report for the third quarter ending December 31, 2025, to the stock exchanges. This is a routine SEBI-mandated compliance filing required from companies that have raised capital through public or preferential issuances. The monitoring agency tracks whether the funds raised from investors are being deployed for the purposes originally disclosed to shareholders. No deviation, misuse of proceeds, or material concern has been flagged in the public headline.
This is largely a procedural compliance disclosure and is neutral for shareholders in the absence of any adverse observations. Investors should review the attached report to confirm there are no deviations from the stated use of proceeds, which would be the only trigger for a negative reaction.